# TAK-771 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tak-771

> The FDA approved TAK-771, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on Jun 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TAK-771 |
| Codes | TAK-771 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [Primary Immunodeficiency Diseases (PID)](https://sec-api.dev/indications/primary-immunodeficiency-diseases-pid), [Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)](https://sec-api.dev/indications/chronic-inflammatory-demyelinating-polyradiculoneuropathy-cidp) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### March 18, 2025: topline data readout

- Status: completed. Date confidence: exact. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05084053 (A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2025-03-18." https://clinicaltrials.gov/study/NCT05084053?tab=results

### Jun 2025: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-10-30, last confirmed 2026-05-26.
- Press release filed with the SEC (EX-99) (accession 0001395064-26-000162): "GAMMAGARD LIQUID ERC / Generic name: Immunoglobulin (IG) Infusion 10% (Human) (Low IgA) - In June 2025, Takeda announced that the U.S. Food and Drug Administration (FDA) approved GAMMAGARD LIQUID ERC with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI)." https://www.sec.gov/Archives/edgar/data/1395064/000139506426000162/noticeofconvocationofthe.htm
- SEC Form 8-K (accession 0001395064-25-000154): "-In June 2025, Takeda announced that the U.S. Food and Drug Administration (FDA) approved GAMMAGARD LIQUID ERC with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI)." https://www.sec.gov/Archives/edgar/data/1395064/000139506425000154/form6k-3_103025.htm

### October 28, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05084053 (A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2025-03-18." https://clinicaltrials.gov/study/NCT05084053

### October 30, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Primary Immunodeficiency Diseases (PID).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05513586 (A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-19." https://clinicaltrials.gov/study/NCT05513586

### May 19, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Primary Immunodeficiency Diseases (PID).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05513586 (A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-30 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-05-19." https://clinicaltrials.gov/study/NCT05513586?tab=results

## Same indication

- [Hypersialylated immune globulin g](https://sec-api.dev/pdufa/hypersialylated-immune-globulin-g) (TAK)
- [TAK-881](https://sec-api.dev/pdufa/tak-881) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tak-771.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TAK-771 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tak-771

```bibtex
@misc{secapidev_pdufa_tak_771_20261116,
  title        = {TAK-771 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tak-771}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tak_771_20261116","title":"TAK-771 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tak-771","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
